TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1418507

Group type: EXPERIMENTAL
Intervention: DuoDERM Burn Pack Hydroactive Dressings (DHD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: silver sulphadiazine/Bactigras dressings (SSD/Bactigras)
Number of subjects: 48
Study: 6702863

Group type: EXPERIMENTAL
Intervention: Bendrofluazide (thiazide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide treatment
Number of subjects: 0
Study: 30442030

Group type: EXPERIMENTAL
Intervention: Prolonged slow expiration respiratory physiotherapy treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 80
Study: 30066937

Group type: EXPERIMENTAL
Intervention: Aloe polysaccharide (APS) at doses of 20, 40, and 80 µg/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aloe polysaccharide (APS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF-a
Number of subjects: 0
Study: 27217345

Group type: EXPERIMENTAL
Intervention: Low-dose ASCs (2 × 10(6) cells)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Medium-dose ASCs (10 × 10(6) cells)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-dose ASCs (50 × 10(6) cells)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All doses of ASCs
Number of subjects: 18
Study: 24675507

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 132

Group type: COMPARATOR
Intervention: best supportive care
Number of subjects: 132
Study: 23008325

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU), cisplatin, and interferon alfa‐2b (IFN α‐2b) plus radiotherapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Fluorouracil (FU) monotherapy
Number of subjects: 132
Study: 20362850

Group type: EXPERIMENTAL
Intervention: Low fluidic parameters (aspiration flow rate 25 cc/min; bottle height 70 cm and 90 cm; vacuum ≤400 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High fluidic parameters (aspiration flow rate 40 cc/min; bottle height 90 cm and 110 cm; vacuum ≤650 mm Hg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low fluidic parameters
Number of subjects: 0

Group type: COMPARATOR
Intervention: High fluidic parameters
Number of subjects: 0
Study: 18613861

Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg, 200 mg, and 400 mg single doses (study 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg twice daily for 7 days (study 2)
Number of subjects: 24
Study: 15970290

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day for 6 months)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (3.9 mg/week for 6 months)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 11854872

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia combined with general anesthesia during surgery and epidural analgesia for the first 24 postoperative hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia during surgery and intravenous opiate analgesia after surgery
Number of subjects: 60
Study: 11703279

Group type: EXPERIMENTAL
Intervention: Oral liarozole 75 mg twice daily for 12 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9413412

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 52
Study: 8314680

Group type: EXPERIMENTAL
Intervention: H.E.L.P. application (Group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: H.E.L.P. application (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 42
Study: 3725001

Group type: EXPERIMENTAL
Intervention: Amitriptyline (200 mg)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Trazodone (400 mg)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 31996411

Group type: EXPERIMENTAL
Intervention: Amiloride/hydrochlorothiazide (5 mg/50 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dietary sodium restriction (60 mmol per day)
Number of subjects: 26
Study: 29718920

Group type: EXPERIMENTAL
Intervention: Placental cord drainage
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (not submitted to placental cord drainage)
Number of subjects: 226
Study: 27180444

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olmetec Plus 20/12.5 mg
Number of subjects: 0
Study: 26214787

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sevoflurane with BIS monitoring
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol with BIS monitoring
Number of subjects: 100
Study: 23763557

Group type: EXPERIMENTAL
Intervention: 5% lidocaine applied using the DASD
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control device
Number of subjects: 50
Study: 21148499

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 3.7 × 10(5) PFU
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 3.7 × 10(4) PFU
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 3.7 × 10(3) PFU
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 3.7 × 10(5) PFU (part 2)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (part 2)
Number of subjects: 4
Study: 18294393

Group type: EXPERIMENTAL
Intervention: Individualized NYHA adapted protocol (5 or 10 Watt/min stages)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standardized Jones protocol (16 Watt per minute stages)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 22
Study: 17163251

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 60
Study: 12669745

Group type: EXPERIMENTAL
Intervention: Perceptual organization processes in visual agnosia
Number of subjects: 2
Study: 10880159

Group type: EXPERIMENTAL
Intervention: Hepatic artery chemotherapeutic embolization combined with perfusing LAK cells/interleukin 2
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hepatic artery chemotherapeutic embolization
Number of subjects: 42
Study: 7503472

Group type: EXPERIMENTAL
Intervention: Event monitors
Number of subjects: 43

Group type: COMPARATOR
Intervention: 48-hour Holter monitoring
Number of subjects: 43
Study: 1564675

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 35
Study: 28837819

Group type: EXPERIMENTAL
Intervention: Visual exposure to vegetables (place mats with pictures of vegetables for 2 weeks)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Diverse visual exposure to vegetables (varying in color)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Visual exposure to vegetables
Number of subjects: 70
Study: 27037091

Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 1,800 mg once-daily
Number of subjects: 556
Study: 25910081

Group type: EXPERIMENTAL
Intervention: Home food environment characteristics (e.g., healthy shopping, selecting healthy beverages, healthy food preparation, serving behaviors)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Eating while watching television
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Home food environment factors
Number of subjects: 198

Group type: COMPARATOR
Intervention: Demographic characteristics
Number of subjects: 198
Study: 23497000

Group type: EXPERIMENTAL
Intervention: Multifactorial Falls Prevention Program (12-week duration)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Multifactorial Falls Prevention Program
Number of subjects: 612

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 612
Study: 19716266

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions with placebo or blinded care providers
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Sample size greater than 100 patients
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Trial quality measures (blinding, placebo use, allocation procedure, overall quality)
Number of subjects: 184
Study: 18794646

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 93

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 93
Study: 16647914

Group type: EXPERIMENTAL
Intervention: Gynecological treatment plus somatocognitive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard gynecological treatment
Number of subjects: 0
Study: 14657888

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 7165

Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 7165
Study: 11122178

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 8843262

Group type: EXPERIMENTAL
Intervention: Carter‐Thomason Needle‐Point Suture Passer
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard technique of hand‐sutured closure
Number of subjects: 32
Study: 1624241

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 50 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Trimethoprim 50 mg
Number of subjects: 38
Study: 6143965

Group type: EXPERIMENTAL
Intervention: Anti-LPS treatment (freeze-dried human plasma rich in anti-LPS immunoglobulin G)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Anti-LPS treatment
Number of subjects: 33
Study: 30898550

Group type: EXPERIMENTAL
Intervention: Deferoxamine mesylate (32 mg/kg per day) for 3 consecutive days
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo (saline) infusions for 3 consecutive days
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Deferoxamine mesylate
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 26899537

Group type: EXPERIMENTAL
Intervention: Short-term statin treatment
Number of subjects: 7746

Group type: EXPERIMENTAL
Intervention: High-dose statins
Number of subjects: 7746
Study: 25412647

Group type: EXPERIMENTAL
Intervention: Influenza immunization in healthy children
Number of subjects: 0

Group type: COMPARATOR
Intervention: No immunization (Control)
Number of subjects: 0
Study: 23214255

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bromocriptine + Compound Xuanju Capsule (CXC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bromocriptine + CXC
Number of subjects: 46
Study: 20480414

Group type: EXPERIMENTAL
Intervention: Negative stereotype activation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Positive or neutral stereotype activation
Number of subjects: 117
Study: 16859864

Group type: EXPERIMENTAL
Intervention: Counseling intervention (1.5 hours of counseling plus telephone follow-up by a masters prepared mental health counselor)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care (standard cessation advice from the health care provider)
Number of subjects: 105
Study: 15851220

Group type: EXPERIMENTAL
Intervention: Optimized AV delay determined by Doppler echocardiography (group 1, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empiric AV delay of 120 ms (group 2, n = 20)
Number of subjects: 40
Study: 11094650

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous hormone replacement therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies of ERT
Number of subjects: 0
Study: 9156960

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 10
Study: 8438612

Group type: EXPERIMENTAL
Intervention: Parenteral administration of a killed typhoid vaccine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Parenteral vaccination
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral vaccination
Number of subjects: 17
Study: 3514550

Group type: EXPERIMENTAL
Intervention: relaxation with EMG and thermal biofeedback
Number of subjects: 16

Group type: COMPARATOR
Intervention: person‐centered insight therapy
Number of subjects: 16
Study: 30308524

Group type: EXPERIMENTAL
Intervention: GlideScope laryngoscope
Number of subjects: 44

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 44
Study: 28587621

Group type: EXPERIMENTAL
Intervention: Brief, structured intervention (self-help booklet + one proactive call)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (motivational interviewing with tailored proactive and reactive calls)
Number of subjects: 300
Study: 25941016

Group type: EXPERIMENTAL
Intervention: AVP-825 (22 mg sumatriptan powder)
Number of subjects: 275

Group type: COMPARATOR
Intervention: 100 mg oral sumatriptan
Number of subjects: 275
Study: 23712687

Group type: EXPERIMENTAL
Intervention: Mechanical noise applied to ankle muscle tendons at mean amplitudes of 20, 30, 100, and 280 μm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microneurography without noise application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microneurography with optimal level of noise application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cutaneous afferents with and without noise application
Number of subjects: 0
Study: 21431391

Group type: EXPERIMENTAL
Intervention: S-POP system
Number of subjects: 511
Study: 20559976

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) peri-infarct pacing delivered via biventricular pacemakers
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study: 17893569

Group type: EXPERIMENTAL
Intervention: Low proportions of CD3+CD4+CD69+ cells before treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low proportions of CD3+CD56+ cells before treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pretreatment proportion of CD3+CD4+CD69+ cells
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pretreatment proportion of CD3+CD56+ cells
Number of subjects: 31
Study: 16371039

Group type: EXPERIMENTAL
Intervention: PCT apheresis PLTs
Number of subjects: 645
Study: 11952312

Group type: EXPERIMENTAL
Intervention: CTF-guided puncture (group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sequential CT-guided puncture (group B)
Number of subjects: 75
Study: 9607383

Group type: EXPERIMENTAL
Intervention: 100 mg losartan
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: 300 mg irbesartan
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study: 8582490

Group type: EXPERIMENTAL
Intervention: Deliveries directed by obstetricians
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Primiparous deliveries
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Midwives and general practitioners
Number of subjects: 1034
Study: 1700218

Group type: EXPERIMENTAL
Intervention: Low-dose 443C81 (0.46 +/- 0.11 microgram/ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-dose 443C81 (1.0 +/- 0.2 microgram/ml)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both doses of 443C81
Number of subjects: 6
Study: 359266

Group type: EXPERIMENTAL
Intervention: Hot water by sip
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hot chicken soup by sip
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hot chicken soup by straw
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cold water by sip
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham drinking procedure with straw
Number of subjects: 15
Study: 30515978

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 124

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study: 28178150

Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty (SLT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%)
Number of subjects: 60
Study: 25270327

Group type: EXPERIMENTAL
Intervention: Spontaneous walking speed with backward counting task
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Very slow walking speed with backward counting task
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Slow walking speed with backward counting task
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sitting with cognitive performance assessment
Number of subjects: 22
Study: 23629874

Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1)pdm09
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Influenza B
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1) and A(H3N2)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Older index cases (age 11-14 years)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Younger infected household contacts (age ≤15 years)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Greater time spent in proximity to the index child
Number of subjects: 566
Study: 21654265

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol 200 mg/d
Number of subjects: 0
Study: 19494806

Group type: EXPERIMENTAL
Intervention: SNPs from DRD2, SLC6A3, and NR4A2 genes
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: SLC6A3 SNPs
Number of subjects: 828

Group type: COMPARATOR
Intervention: Community cohort of N=175 multiplex ever-smoking pedigrees (N=423 ever smokers)
Number of subjects: 828
Study: 16936143

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2155
Study: 14574579

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x (5 g Cr monohydrate + 2.5 g maltodextrin)/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo supplementation (4 x 7.5 g maltodextrin/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 12
Study: 11157325

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (molar ratio 0.6:1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Na2EDTA (molar ratios 0.3:1, 0.7:1, 1:1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no added enhancers)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (molar ratio 1.6:1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Na2EDTA (molar ratio 0.7:1)
Number of subjects: 19
Study: 9776870

Group type: EXPERIMENTAL
Intervention: Combined exercise training and dietary program in hypertensive group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Combined exercise training and dietary program in normotensive group
Number of subjects: 56
Study: 8159193

Group type: EXPERIMENTAL
Intervention: Six-week taper period
Number of subjects: 149

Group type: COMPARATOR
Intervention: Nine-month taper period
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mental retardation presence
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Spikes in the electroencephalogram at tapering
Number of subjects: 149
Study: 2659720

Group type: EXPERIMENTAL
Intervention: Elemental diet (Pepti 2000)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Blended normal diet (placebo)
Number of subjects: 43
Study: 768955

Group type: EXPERIMENTAL
Intervention: 780SE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31486660

Group type: EXPERIMENTAL
Intervention: Neutral third-party perspective reappraisal
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Other party's perspective reappraisal
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control (reflecting on daily activities)
Number of subjects: 190
Study: 28951468

Group type: EXPERIMENTAL
Intervention: Protocolized management of NIV
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-protocolized management of NIV (control group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Total sample (both groups)
Number of subjects: 47
Study: 26047993

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2292

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 2292
Study: 21306457

Group type: EXPERIMENTAL
Intervention: Relaxation therapy (20 minutes daily from the day before surgery to the third postoperative day)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no relaxation therapy)
Number of subjects: 93
Study: 19967423

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered once a week (QW)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Darbepoetin alfa administered every 2 weeks (Q2W)
Number of subjects: 39
Study: 18929239

Group type: EXPERIMENTAL
Intervention: No anticoagulation therapy (no-heparin arm)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard anticoagulation regimen (control arm: 70 to 100 UI/kg unfractionated heparin)
Number of subjects: 700
Study: 15876753

Group type: EXPERIMENTAL
Intervention: Conventional education
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control
Number of subjects: 272
Study: 11806881

Group type: EXPERIMENTAL
Intervention: 10 mg oral loratadine, once daily for three days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10075338

Group type: EXPERIMENTAL
Intervention: Fe group (60 mg Fe and 250 microg folate)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fe+Zn group (60 mg Fe, 250 microg folate, and 15 mg Zn)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no prenatal supplementation)
Number of subjects: 45
Study: 8613581

Group type: EXPERIMENTAL
Intervention: Daily toothbrushing programme with fluoride dentifrice
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Daily toothbrushing programme with fluoride dentifrice plus weekly 0.2% fluoride rinse
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (De Villiers cohort)
Number of subjects: 150
Study: 2124097

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (uninfected Zaireans)
Number of subjects: 28